anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention can inhibit the proliferation of blood vessel endothelium and resist the regeneration activity of tumour blood vessel, so that it can be used as a biological prepn. in the treatment of tumour. The characterisitc lies in that: (a). human endostain gene is obtd. from human collagen-albumen 18gene 1503-2055 cDNA active section and selected from human liver cDNA pool through PCR; (b) two kinds of gene section are obtd. from human endostain gene by endonuclease; (c). human endostatin gene and two kinds of gene section obtd. in term (b) are expressed in colon bacillus through the gene clone method.
A patient management system (100) for managing an assignment to a patient, includes a plurality of patient identifiers (110). The patient identifiers are intended for use by a medical staff. Each of the patient identifiers, in which patient-specific information (112) is stored, is assigned to a corresponding one of a plurality of patients. A mobile user carrier device (120) is configured to store a plurality of patient identifiers, so that a number of patient identifiers currently being stored at the mobile user carrier device can be visually recognized. The mobile user carrier device has an energy storage device (122) and a communication interface (124). The mobile user carrier device is configured to read out the respective patient-specific information of the patient identifiers being stored at the mobile user carrier device, at least partially, and to output same wirelessly via the communication interface.
This trial is a single-arm, open-label, exploratory trial, and no statistical hypothesis is made for sample size estimation. It is planned to enroll approximately 30 participants to receive CT011 infusion.
Diverse animal models have been used to study postpancreatitis diabetes mellitus (PPDM) development; however, no study has yet conducted a comparative analysis of the specific differences in glucose homeostasis and islet injury between these models. Therefore, we investigated the differences in pancreatic islet injury and glucose homeostasis among diverse strains in a cerulein-induced acute pancreatitis (AP) model to determine the appropriate animal model for PPDM. BALB/cJ, C57BL/6J, C57BL/6 N, and FVB/NJ mice were administered cerulein to induce AP. Serum amylase levels, pancreatic acinar injury, blood glucose homeostasis, islet function, and islet injury were measured and analyzed. All strains exhibited elevated amylase secretion post pancreatitis, and BALB/cJ, C57BL/6J, and C57BL/6 N mice exhibited sex-related differences. All strains exhibited pancreatic acinar injury post pancreatitis but mostly recovered within 15 days. Overall, glucose homeostasis remained balanced post pancreatitis in all strains compared to that in the control groups, except in FVB/NJ male and female mice, which exhibited an imbalance in glucose homeostasis on day 7 post pancreatitis. All the strains, except BALB/cJ mice, exhibited a decline in Homeostasis model assessment-β(HOMA-β) values post pancreatitis, with significant decrease in C57BL/6J females and FVB/NJ males. Islet size decreased post pancreatitis in all strains, except BALB/cJ mice. Pancreatic islet insulin secretion levels significantly decreased in male FVB/NJ mice post pancreatitis onset and did not recover within 15 days. Therefore, FVB/NJ male mice are a useful model for studying PPDM.
This is a multicenter (study conducted at multiple sites), randomized (the study medication is assigned by chance), double-blind (neither investigator nor the patient knows the treatment that the patient receives), placebo-controlled (an inactive substance that is compared with the study medication to test whether the study medication has a real effect in clinical study), dose-ranging study (study carried out at different doses) to evaluate the analgesic efficacy, safety, and tolerability of multiple doses of JNJ-42160443 in patients with neuropathic pain, followed by a double-blind safety extension and an open-label (all people know the identity of the intervention) safety extension. The study will consist of 5 sequential phases: 1) screening, 2) a 12-week double-blind efficacy, 3) a 40-week double-blind safety extension, 4) a 52-week open-label safety extension, and 5) a 26-week post-treatment/follow-up. After the screening phase, patient randomization will be stratified by current pain medication use (patients who are currently using or who are not currently using permitted pain medication). The planned doses for the double-blind efficacy phase and double blind safety extension phase are placebo, JNJ-42160443 1, 3, or 10 mg administered as a single, subcutaneous injection every 28 days. Safety assessment will include adverse events, injection site evaluations, clinical laboratory tests, electrocardiogram, vital signs, physical examinations, neurological examinations, and joint safety which will be monitored throughout the study. The total study duration (including all the 5 phases) will be approximately 131 weeks.
Belonging to the technical field of medicinal preparations, the invention discloses a diltiazem hydrochloride delayed release bilayer osmotic pump controlled released tablet and its preparation method. The preparation is composed of a diltiazem hydrochloride-containing tablet core, a water-soluble polymeric membrane, and a semipermeable coating membrane with drug release holes. The table core comprises a drug-containing layer, which is made up of 12g of diltiazem hydrochloride, 0.5-8g of an osmotic pressure active material, 10g-30g of a suspension, and 0.2g-0.7g of a lubricant, and a boosting layer composed of 5g-15g of a swelling agent and 0.5g-5g of an osmotic pressure active material. The water-soluble polymeric membrane contains 50g-100g of a polymer material. The semipermeable coating membrane is made of 10-20g of a semipermeable polymer material and 2g-6g of a water-soluble pore forming agent. The water-soluble polymeric isolating membrane accounts for 12%-50% of the weight of the tablet core, and the coating membrane accounts for 6%-12% of the weight of the tablet core. And two drug release holes are disposed on sides of the drug-containing layer in a coated tablet. Characterized by constant speed and delayed release, the controlled released tablet of the invention can generate stable plasma concentration, improve patient compliance, and reach good lipid regulating effect.
PURPOSE: A multi layer food manufacturing device and a method thereof are provided to produce multi layer food including dumplings by wrapping an internal food material including filling using a hard external food material. CONSTITUTION: An internal food material feed unit (20) includes an internal food material transferring device (22) which is capable of transferring internal food materials by force. An external food material feed unit (30) includes an external food material transferring device (32) which is capable of transferring external food materials by force. A discharging unit (40) discharges the internal or external food materials. The internal food material transferring device and the external food material transferring device include a one-axis eccentric screw pump (200) with a rotor and a stator. A controller controls the transfer of the internal or external food materials. The internal food material feed unit includes an internal food material storage tank (24) and a stirrer (26). The external food material feed unit includes an external food material storage tank (34). The external food material transferring device includes a pump unit (35) with the one-axis eccentric screw pump, a driving unit (36), and a connection unit (38).
PURPOSE: To assess the role of the p160 family, AR, and AR-V7 in different initial presentations of prostate cancer and their association with clinical endpoints related to tumor progression.
METHODS: The study sample comprises 155 patients who underwent radical prostatectomy and 11 healthy peripheral zone biopsies as the control group. Gene expression was quantified by qPCR from the tissue specimens. The statistical analysis investigated correlations between gene expression levels, associations with disease presence, and clinicopathological features. Additionally, ROC curves were applied for distinct PCa presentations, and time-to-event analysis was used for clinical endpoints.
RESULTS: The AR-V7 diagnostic performance for any PCa yielded an AUC of 0.77 (p < 0.05). For locally advanced PCa, the AR-V7 AUC was 0.65 (p < 0.05). Moreover, the metastasis group had a higher expression of SRC-1 than the non-metastatic group (p < 0.05), showing a shorter time to metastasis in the over-expressed group (p = 0.005). Patients with disease recurrence had super-expression of AR levels (p < 0.0005), with a shorter time-to-recurrence in the super-expression group (p < 0.0001).
CONCLUSION: Upregulation of SRC-1 indicates a higher risk of progression to metastatic disease in a shorter period, which warrants further research to be applied as a clinical tool. Additionally, AR may be used as a predictor for PCa recurrence. Furthermore, AR-V7 may be helpful as a diagnostic tool for PCa and locally advanced cancer, comparable with other investigated tools.
OBJECTIVE: Etiology of vocal cord paralysis (VCP) and laryngeal dysfunction may be congenital or surgical trauma of recurrent and superior laryngeal nerves. We assessed the incidence, risk factors, and morbidity of VCP after repair of esophageal atresia (EA).
METHODS: Medical records of 201 EA patients from 2000 to 2022 were reviewed for this retrospective study. Postrepair vocal cord examination (VCE) included awake nasolaryngeal fiberoscopy by otolaryngologist or laryngoscopy under spontaneous breathing anesthesia. Before 2017, postoperative VCE was performed in symptomatic patients only and routinely after 2017.
MAIN RESULTS: Overall, VCE was performed on 79 (38%) patients (52 asymptomatic), whereas 122 asymptomatic patients underwent no VCE. VCP was diagnosed in 32 of 79 patients (right 12, left 10, and bilateral 10; symptomatic 25 and asymptomatic unilateral 7) corresponding with extrapolated overall VCP incidence of 16 to 24% among 201 patients including asymptomatic ones. Ten patients (bilateral VCP 8 and left VCP 2) required tracheostomy. Of 10 patients with bilateral VCP, three underwent laryngotracheal expansion surgery (left VC lateralization in one and laryngoplasty in two with acquired subglottic stenosis), three remained tracheostomy dependent, three were off tracheostomy, and one died of complications after redo esophageal reconstruction. All patients with unilateral VCP managed without tracheostomy. Cervical dissection or ostomy formation was a major risk factor of VCP.
CONCLUSION: Repair of EA is associated with a considerable risk of VCP and associated morbidity. Cervical EA surgery significantly increased the risk of VCP. Bilateral VCP may eventually require laryngotracheal expansion surgery.
Sterile inflammation, also known as 'inflammaging', is a hallmark of tissue aging. Cellular senescence contributes to tissue aging, in part, through the secretion of proinflammatory factors collectively known as the senescence-associated secretory phenotype (SASP). The genetic variability of thioredoxin reductase 1 (TXNRD1) is associated with aging and age-associated phenotypes such as late-life survival, activity of daily living and physical performance in old age. TXNRD1's role in regulating tissue aging has been attributed to its enzymatic role in cellular redox regulation. Here, we show that TXNRD1 drives the SASP and inflammaging through the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) innate immune response pathway independently of its enzymatic activity. TXNRD1 localizes to cytoplasmic chromatin fragments and interacts with cGAS in a senescence-status-dependent manner, which is necessary for the SASP. TXNRD1 enhances the enzymatic activity of cGAS. TXNRD1 is required for both the tumor-promoting and immune surveillance functions of senescent cells, which are mediated by the SASP in vivo in mouse models. Treatment of aged mice with a TXNRD1 inhibitor that disrupts its interaction with cGAS, but not with an inhibitor of its enzymatic activity alone, downregulated markers of inflammaging in several tissues. In summary, our results show that TXNRD1 promotes the SASP through the innate immune response, with implications for inflammaging. This suggests that the TXNRD1-cGAS interaction is a relevant target for selectively suppressing inflammaging.
Intervention group participants will be recruited from cancer patients in need of palliative care at Tata Medical Center (TMC), Kolkata, India. Pal-Care will be delivered over a 6-month period. At baseline visit, the patient and their caregiver will meet with their community health worker (CHW) and clinical team and an individualized care plan will be created. Patients will be assigned to the CHW living nearest to their home. The CHW will make home visits to patients 1+ times weekly, depending on patient need. At each visit, the CHW will use resources from the WHO Palliative Care Toolkit to: 1)monitor patient condition, 2) provide basic palliative care (medication administration, wound care, catheter care), 3) deliver prescribed morphine, 4) teach caregivers to deliver care,5) monitor pain and symptom control, and 6) assist patients to access their oncologists and other resources. Timely communication between CHW and clinical team will be maintained using a tele-health platform.
The invention relates to the technical field of immunology and antibody engineering, in particular to an anti-PD-L1 humanized monoclonal antibody and application thereof. The CDR-H1 of the heavy chain variable region of the antibody is an amino acid sequence shown by SEQ ID NO. 1, the CDR-H2 is an amino acid sequence shown by SEQ ID NO. 2, and the CDR-H3 is an amino acid sequence shown by SEQ ID NO. 3; and the CDR-L1 of the light chain variable region of the antibody is the amino acid sequence shown in SEQ ID NO. 4, the CDR-L2 is the amino acid sequence shown in SEQ ID NO. 5, and the CDR-L3 is the amino acid sequence shown in SEQ ID NO. 6. The anti-PD-L1 monoclonal antibody provided by the invention has a brand new sequence, can be specifically combined with human PD-L1 protein, has high affinity, enables immune cells to specifically recognize and kill cancer cells, achieves the aim of treating cancer, and has molecular cell level expression not lower than that of the currently sold products.
The invention relates to a traditional Chinese medicine preparation, in particular to a traditional Chinese medicine preparation for treating yin deficiency and lung heat type bacterial pneumonia. The traditional Chinese medicine preparation is characterized in that the traditional Chinese medicine preparation is prepared from, by weight, 20-30 parts of flickingeria comata, 20-30 parts of carapax trionycis, 10-15 parts of chorophytum comosum, 10-15 parts of Oreas martiana (Hopp. Et Hornsch.) Brid., 20-30 parts of circaea quadrisulcata, 15-20 parts of Lotus corniculatus L., 10-15 parts of Gaultheria hookeri C.B. Clarke, 10-15 parts of marsdenia longipes, 20-30 parts of ginseng, 10-15 parts of radix paeoniae rubra and radix paeoniae alba, 10-15 parts of concha ostreae and 5-10 parts of radix aconiti carmichaeli. The traditional Chinese medicine preparation has the advantages that the traditional Chinese medicine materials used by the traditional Chinese medicine preparation conform to the regulations of the Chinese pharmacopoeia, the traditional Chinese medicine materials are combined to achieve synergic effects such as nourishing yin and clearing heat, moistening the lung and relieving cough, and restoring yang and rescuing a patient from collapse, and the traditional Chinese medicine preparation is definite in curative effect on the yin deficiency and lung heat type bacterial pneumonia, quick in action, high in cure rate, free of side effect, and the like.
PURPOSE:To provide an acidic rinsing agent capable of attaining the pH value adequate to keep the protein and the skin in healthy state and keeping stably its effect when diluted to a specific ratio, by using an organic acid and a buffering agent as essential components, and adjusting the pH to a specific level. CONSTITUTION:The objective acidic rinsing agent contains 0.08-30.00(wt)% organic acid selected from citric acid, malic acid, lactic acid, tartaric acid, succinic acid, levulinic acid, aspartic acid, glutamic acid, ascorbic acid, etc. and 0.1-20.0% buffering agent selected from sodium citrate, sodium malate and arginine, and has a pH adjusted to 5.30-3.75 (at 20 deg.C). The composition further contains 1-5% humectant, 0.3-3% surfactant, 0.3-1% silicone oil, etc. (in terms of concentration in use). The product is suitable for the pH-control of the oxidizing agent in acidic permanent wave treatment, the rinsing in hair dyeing operation, etc.
FIELD: cosmetics, dermatology. SUBSTANCE: invention relates to cosmetic and/or compositions used as photoprotecting agents for skin and/or hair and containing in cosmetically acceptable medium, in part, in emulsion of type "oil-in-water": (i) sulfone derivative of benzimidazole as the first screening agent and (ii) silicone derivative containing benzotriazole group as the second screening agent. The first and the second screening agents are taken in the composition at molar ratio that provides synergistic effect with respect to activity making by sun-protecting factors. Invention involves also a method of photoprotection by applying the indicated composition on skin and/or hair. EFFECT: improved properties and effectiveness of the composition. 11 cl, 2 tbl, 1 ex
Previous research has shown that parent-implemented interventions are effective in improving the social skills of children with autism spectrum disorder (ASD).Considering that several differences in social and non-social skills start to emerge before a diagnosis can be made, this project aims to investigate the effects of an adapted prodromal version of an evidence-based parent-mediated intervention (Project ImPACT) in children with an elevated likelihood to develop ASD (namely siblings and children who were born preterm). The effect of the intervention will be evaluated at both behavioural and neural levels. The intervention is suitable for infants and consists of 12 session with the child and his/her parents, of maximum 2 hours each, one session per week, delivered by therapists of the home guidance and home guidance centers in Flanders. Children between 9 and 18 months old and their parents will participate in the study. They will be randomly assigned to the ImPACT intervention group or a no-intervention group (monitoring only). The families will be invited to come to the Faculty of Psychology and Pedagogical Sciences at three time points: before the start of the intervention, immediately after the end of the intervention (which is expected to last 12 weeks) and 24 weeks after the end of the intervention.
The present invention relates to a composition comprising a betulinic acid or a derivative of the same for enhancing physical strength. The composition of the present invention has an excise performance enhancing ability, an endurance enhancing ability, and stress controlling ability. The betulinic acid of the present invention is a compound having a structure of the following chemical formula 1. The betulinic acid of the present invention is derived from nature or is chemically synthesized for usage. In addition, the betulinic acid derivative of the present invention has a hydroxyl group or a carboxyl group of a betulinic acid substituted. The betulinic acid derivative of the present invention is nature-derived or chemically synthesized to be applied.
Elderly patients, particularly those with reduced renal or hepatic function, may be at increased risk for developing erythromycin-induced hearing loss. (See ADVERSE REACTIONS and DOSAGE AND ADMINISTRATION).

Elderly patients may be more susceptible to the development of torsades de pointes arrhythmias than younger patients. (See ADVERSE REACTIONS).

Elderly patients may experience increased effects of oral anticoagulant therapy while undergoing treatment with erythromycin. (See PRECAUTIONS \- Drug Interactions).

Erythrocin Stearate Filmtab ® Tablets (250 mg) contain 56.7 mg (2.5 mEq) of sodium and 5.0 mg (0.1 mEq) of potassium per tablet.

Erythrocin Stearate Filmtab ® Tablets (500 mg) contain no sodium and 7.0 mg (0.2 mEq) of potassium per tablet.

The geriatric population may respond with a blunted natriuresis to salt loading. This may be clinically important with regard to such diseases as congestive heart failure.
Thyroid disease during pregnancy has been associated with multiple adverse outcomes including miscarriage, preterm delivery, postpartum thyroiditis and decreased IQ in the offspring. Whether or not all women should be screened for thyroid disease during pregnancy (Universal Screening), screening should be confined to women at high risk for thyroid disease (Case Finding), or no screening should occur is controversial. For this purpose, pregnant women in the first trimester are randomly assigned to the Screening group or Case finding group. All women in the Screening group and high-risk women in the Case Finding group are immediately tested for FT4, TSH and TPO antibodies. Low-risk women in the Case Finding group have their sera tested postpartum. levothyroxine or PTU are given in hypothyroid and hyperthyroid women respectively. Outcome Measure: total number of adverse events occurring during pregnancy and in the neonatal period controlling for clustering of outcomes within women.
Oxaliplatin is the third generation platinum-based cytotoxic agent, widely used in colorectal cancer, in metastatic disease and in the adjuvant setting . Moreover, oxaliplatin is being used as an alternative option to cisplatin in various cancers, such as ovarian, gastric. Oxaliplatin-induced peripheral neuropathy is characterised by acute and transient cold hyperaesthesia in the hours and days following oxaliplatin infusion (\>90% of patients), but also by retarded chronic neuropathy due to the repetition of chemotherapy cycles (30-50% of patients). Oxaliplatin-induced peripheral neuropathy impairs the health-related quality of life (HRQOL) of patients and no preventive or curative strategies have as yet proven effective so far. Animal experiment show that HD6610 granule can relieve mouse's peripheral neuropathy induced by oxaliplatin. In clinical practice, the investigators also find that HD6610 granule can relieve patient's oxaliplatin-induced peripheral neuropathy in the treatment of chemotherapy. So the investigators design this randomized, parallel-group, double-blind, placebo-controlled, multicenter clinical study to estimate the efficacy and safety of HD6610 granule for oxaliplatin-induced peripheral neuropathy in colorectal cancer.
The Wnt/beta-catenin pathway plays a crucial role in regulating cellular processes and has been implicated in neural activity-dependent learning as well as anxiety. However, the role of this pathway in young children with abnormal cortical development is unknown. Cortical malformations at early development, behavioral abnormalities, and a susceptibility to seizures have been reported in rats prenatally exposed to methylazoxymethanol. In this study, we aimed to investigate whether we could improve the behavioral deficits in young rats with malformed cerebral cortices by modulation of the Wnt/beta-catenin pathway. We found a small molecule Wnt/beta-catenin inhibitor (CWP) that increased exploratory behavior in the open field test (P9, CWP 100 ug treatment, peripheral exploration, P = 0.011) and social behavior test (P12, CWP 250 ug treatment, distance traveled in center, P = 0.033) and decreased anxiety in fear conditioning. However, it did not reduce the susceptibility to seizures. After high dose (250 ug) CWP treatment at P12, phosphocreatine and glutathione (GSH) were decreased in the cortex at P15 (P = 0.021). These findings suggest that the role of Wnt/beta-catenin signaling in exploratory behavior and anxiety during early development warrants further investigation.